Erasca, Inc. Investors Alerted About Class Action Deadline: Important Information Inside

Urgent Alert for Erasca, Inc. Investors

Erasca, Inc. (NASDAQ: ERAS) has recently found itself embroiled in a securities class action lawsuit, and the deadline for investors to join the legal action is fast approaching. Investors who purchased shares during the designated class period from January 14, 2025, to April 26, 2026, are being urged to take action before the deadline of August 10, 2026.

Concerns Over ERAS-0015

The lawsuit raises serious allegations against Erasca's management regarding the promotion of its drug candidate, ERAS-0015. Investors claim that the company misled them by advertising ERAS-0015 as a "best-in-class" treatment option, while concealing significant risks, including a patent infringement notice and details of a patient's death that occurred during clinical trials. Following two critical disclosures on April 27, 2026, the stock price plummeted by 53.9%, resulting in a loss of $11.59 per share.

Details of the Allegations

1. Patent Infringement Risk: The lawsuit indicates that Erasca failed to disclose a letter from Revolution Medicines alleging patent infringement related to the technology utilized in ERAS-0015.

2. Patient Safety Concerns: There were serious treatment-related adverse events, including one case where a patient suffered from pneumonitis that escalated to a Grade 5 event, or death. The company did not communicate this information to shareholders until after the stock's significant decline.

3. Misleading Comparisons: Erasca’s presentations claimed that ERAS-0015 had superior binding affinities and efficacy compared to a competing treatment by Revolution Medicines without disclosing the lack of adequate comparative studies.

The Class Action Lawsuit

The class action was initiated by concerned investors who seek to hold Erasca accountable for allegedly hiding crucial information that would have affected their investment decisions. Legal representatives have emphasized that potential class members can still recoup their losses if they purchased ERAS stocks within the specified timeframe, even if they have sold their shares since then.

Next Steps for Investors

Joseph E. Levi, an attorney representing the investors, encourages affected individuals to gather their brokerage records, including purchase dates and share quantities, and contact him for assistance in evaluating their potential claims. The case highlights the importance of transparency and accountability in corporate communications. Investors who bought shares or experienced losses during the class period are advised to consider this legal action seriously.

Why This Matters

Understanding the details surrounding the allegations against Erasca is imperative for shareholders who were misled about the prospects of ERAS-0015. The pending legal decisions will substantially impact the company’s future and the recovery of losses for investors. Levi & Korsinsky has stated their commitment to supporting victims of corporate misconduct.

For those eligible, participating in the class action is a no-cost endeavor, as securities class actions operate on a contingency basis. Additionally, there’s no requirement for class members to appear in court or provide testimony, making it accessible for all investors.

In conclusion, shareholders should remain vigilant and proactive in protecting their investment rights. With the approaching deadline, now is a critical time for Erasca investors to assess their stance and act accordingly.

Contact for Further Inquiry

For those interested in joining the class action or seeking more information, please reach out to Joseph E. Levi, Esq. at Levi & Korsinsky, LLP, via email at [email protected] or call (212) 363-7500.